Antiprotozoal Agents Chemische Eigenschaften,Einsatz,Produktion Methoden
Antimicrobial activity
Protozoa are unicellular, eukaryotic cells with an enormous diversity of
biological characteristics. This is reflected in the requirements for different
drugs and limited overlap in sensitivity. Several antiprotozoal agents
developed in the 1920s and 1930s (e.g. suramin, mepacrine, chloroquine
and sodium stibogluconate) are still widely used. Standard drugs for the
treatment of the most neglected diseases – human African trypanosomiasis
(sleeping sickness), leishmaniasis and South American trypanosomiasis
(Chagas disease) – remain inadequate, although the introduction
of miltefosine for leishmaniasis has seen a significant improvement in
potential for treatment of this condition. There is still a need to identify
more effective drugs for diseases such as cryptosporidiosis and toxoplasmosis,
which have emerged as important opportunistic pathogens
in immunocompromised patients.
Awareness of the impact of protozoal diseases such as malaria on
the development of many countries, and the spread of drug resistance
(Ch. 62), has led to initiatives to discover and develop new drugs. Large
screening programs are now in place through philanthropic and public
funding and the development of public–private partnerships.
Antiprotozoal Agents Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
